Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Thalidomide in EGFR-mutated NSCLC
NCT02387086Phase 3Unknown
- Start
- May 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of thalidomide in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02387086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387086.